<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00739999</url>
  </required_header>
  <id_info>
    <org_study_id>A2581172</org_study_id>
    <nct_id>NCT00739999</nct_id>
  </id_info>
  <brief_title>8-Week PK/PD Atorvastatin Study In Children And Adolescents With Heterozygous Familial Hypercholesterolemia</brief_title>
  <official_title>A 8-Week, Open-Label, Phase 1 Study To Evaluate Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Atorvastatin In Children And Adolescents With Heterozygous Familial Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate pharmacokinetics, pharmacodynamics, safety and tolerability of atorvastatin in
      children and adolescents with heterozygous familial hypercholesterolemia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Atorvastatin Apparent Clearance (CL/F)</measure>
    <time_frame>Week 2, Week 4, Week 6, Week 8</time_frame>
    <description>Parent-metabolite population PK model built using sparse blood samples from both Tanner Stage 1 and Tanner Stage 2+. Blood sampling times: Weeks 2 and 6: single sample between 4 and 12 hours postdose; Weeks 4 and 8: predose, 1 hour, and 2 hours postdose. Plasma samples were analyzed for atorvastatin and active hydroxyacid metabolite (o-hydroxyatorvastatin) concentrations using a validated, sensitive, and specific high-performance liquid chromatography tandem mass spectrometric method. Data presented are the result of the model used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Apparent Volume of Distribution of the Central Compartment (Vc/F)</measure>
    <time_frame>Week 2, Week 4, Week 6, Week 8</time_frame>
    <description>Parent-metabolite population PK model built using sparse blood samples from Tanner Stages 1 and 2+. Sampling times: Weeks 2 + 6: single sample between 4 -12 hours postdose; Weeks 4 + 8: predose, 1 + 2 hours postdose. Plasma samples analyzed for atorvastatin and active hydroxyacid metabolite (o-hydroxyatorvastatin) concentrations using validated, sensitive, specific high-performance liquid chromatography tandem mass spectrometric method. Vc/F value based on 70 kg body weight. Parameter estimation uncertainty (95% CI) by non-parametric bootstrap analysis. Data presented are result of model used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Pharmacodynamic Responses of Low-density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
    <description>Low-density lipoprotein cholesterol (LDL-C) measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]). Change from baseline = value at observation minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Pharmacodynamic Responses of Low-density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
    <description>Low-density Lipoprotein Cholesterol (LDL-C): percent (%) change from baseline by treatment over time = [LDL-C at observation minus LDL-C at Week 0] divided by LDL-C at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Total Cholesterol (TC)</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
    <description>Total Cholesterol measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]). Change from baseline = value at observation minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol (TC)</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
    <description>Total cholesterol (TC): percent (%) change from baseline by treatment over time = [TC at observation minus TC at Week 0] divided by TC at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Triglycerides (TG)</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
    <description>Change from baseline in triglycerides measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]). Change from baseline = value at observation minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglycerides (TG)</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
    <description>Triglycerides (TG): percent (%) change from baseline by treatment over time = [TG at observation minus TG at Week 0] divided by TG at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
    <description>Change from baseline in high-density lipoprotein cholesterol measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]). Change from baseline = value at observation minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
    <description>High-density lipoprotein cholesterol (HDL-C): percent (%) change by treatment over time = [HDL-C at observation minus HDL-C at Week 0] divided by HDL-C at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Apolipoprotein A-1 (Apo A-1)</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
    <description>Change from baseline in Apolipoprotein A-1 measured in grams per liter (g/L); assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]). Change from baseline = value at observation minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1)</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
    <description>Apolipoprotein A-1 (Apo A-1): percent (%) change from baseline by treatment over time = [Apo A-1 at observation minus Apo A-1 at Week 0] divided by Apo A-1 at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Apolipoprotein B (Apo B)</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
    <description>Change from baseline in Apolipoprotein B measured in grams per liter (g/L); assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]). Change from baseline = value at observation minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B (Apo B)</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
    <description>Apolipoprotein B (Apo B): percent (%) change from baseline by treatment over time = [Apo B at observation minus Apo B at Week 0] divided by Apo B at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C)</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
    <description>Change from baseline in very low-density lipoprotein-cholesterol (VLDL-C) measured in millimoles per liter (mmol/L). Change from baseline = value at observation minus baseline value. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C)</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
    <description>Very low-density lipoprotein-cholesterol (VLDL-C): percent (%) change from baseline by treatment over time = [VLDL-C at observation minus VLDL-C at Week 0] divided by VLDL-C at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Flow-Mediated Dilatation at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Brachial artery flow-mediated dilatation (FMD) = (max minus baseline diameter divided by baseline diameter) x 100%. Standardized image acquisition: brachial artery images recorded for one minute at rest, blood pressure cuff inflated to 250 mm Hg for 5 minutes with brachial artery imaged continuously throughout cuff inflation, cuff released to produce reactive hyperaemia and the brachial artery imaged continuously for 3 minutes after release. Total duration of measurement approximately 25 minutes. Change from baseline = value at observation minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Flow-Mediated Dilatation at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Brachial Flow-Mediated Dilatation (FMD) = (max minus baseline diameter divided by baseline diameter) x 100%.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Pediatric Heterozygous Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>6-10 years will be administered with atorvastatin tablet formulation with initial doses based on age cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>10-17 years will be administered 10-mg daily dose of atorvastatin tablet formulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>6-10 years Tanner Stage 1 will be administered 5-mg daily dose of an atorvastatin pediatric tablet formulation. Dose may be doubled if subjects have not attained target LDL (&lt;3.35 mmol/L) after 4-week treatment.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>10-17 years Tanner Stage 2 will be administered 10-mg daily dose of atorvastatin tablet formulation. Dose may be doubled if subjects have not attained target LDL (&lt;3.35 mmol/L) after 4-week treatment.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Genetically confirmed heterozygous familial hypercholesterolemia (HeFH) with LDL
             greater or equal 4 mmol/L at baseline

        Exclusion Criteria:

          -  Evidence or history of clinically significant diseases, homozygous familial
             hypercholesterolemia (FH)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Greece</country>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A2581172&amp;StudyName=8-Week%20PK/PD%20Atorvastatin%20Study%20In%20Children%20And%20Adolescents%20With%20Heterozygous%20Familial%20Hypercholesterolemia</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2008</study_first_submitted>
  <study_first_submitted_qc>August 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2008</study_first_posted>
  <results_first_submitted>March 15, 2010</results_first_submitted>
  <results_first_submitted_qc>August 19, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 20, 2010</results_first_posted>
  <last_update_submitted>August 19, 2010</last_update_submitted>
  <last_update_submitted_qc>August 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>heterozygous familial hypercholesterolemia (HeFH); atorvastatin; pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at 3 medical centers and participated in the study between 02 December 2008 and 13 May 2009.</recruitment_details>
      <pre_assignment_details>Forty-five subjects were screened, and 39 subjects were assigned to study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin (5 mg, 10 mg): Tanner Stage 1</title>
          <description>Age 6 - 10 years, at Tanner Stage 1. Initial dose 5 mg/day through Week 4; after Week 4 dose may have been doubled to 10 mg/day if target low-density lipoprotein cholesterol (LDL-C) was not attained.</description>
        </group>
        <group group_id="P2">
          <title>Atorvastatin (10 mg, 20 mg): Tanner Stage 2+</title>
          <description>Age 10 - 17 years, at Tanner Stage 2+. Initial dose 10 mg/day through Week 4; after Week 4 dose may have been doubled to 20 mg/day if target LDL-C was not attained.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin (5 mg, 10 mg): Tanner Stage 1</title>
          <description>Initial dose 5 mg/day through Week 4; after Week 4 dose may have been doubled to 10 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
        </group>
        <group group_id="B2">
          <title>Atorvastatin (10 mg, 20 mg): Tanner Stage 2+</title>
          <description>Initial dose 10 mg/day through Week 4; after Week 4 dose may have been doubled to 20 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>6-8 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9-10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11-14 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15-17 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Atorvastatin Apparent Clearance (CL/F)</title>
        <description>Parent-metabolite population PK model built using sparse blood samples from both Tanner Stage 1 and Tanner Stage 2+. Blood sampling times: Weeks 2 and 6: single sample between 4 and 12 hours postdose; Weeks 4 and 8: predose, 1 hour, and 2 hours postdose. Plasma samples were analyzed for atorvastatin and active hydroxyacid metabolite (o-hydroxyatorvastatin) concentrations using a validated, sensitive, and specific high-performance liquid chromatography tandem mass spectrometric method. Data presented are the result of the model used.</description>
        <time_frame>Week 2, Week 4, Week 6, Week 8</time_frame>
        <population>Pharmacokinetic (PK) concentration population: all enrolled and treated subjects who had ≥ 1 PK concentration assessed. Active hydroxyacid metabolite p-hydroxyatorvastatin was not included in the model as originally planned as &gt; 80% of samples were below detectable level at the doses used in this trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin (5 mg, 10 mg): Tanner Stage 1</title>
            <description>Initial dose 5 mg/day through Week 4; after Week 4 dose may have been doubled to 10 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin (10 mg, 20 mg): Tanner Stage 2+</title>
            <description>Initial dose 10 mg/day through Week 4; after Week 4 dose may have been doubled to 20 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Atorvastatin Apparent Clearance (CL/F)</title>
          <description>Parent-metabolite population PK model built using sparse blood samples from both Tanner Stage 1 and Tanner Stage 2+. Blood sampling times: Weeks 2 and 6: single sample between 4 and 12 hours postdose; Weeks 4 and 8: predose, 1 hour, and 2 hours postdose. Plasma samples were analyzed for atorvastatin and active hydroxyacid metabolite (o-hydroxyatorvastatin) concentrations using a validated, sensitive, and specific high-performance liquid chromatography tandem mass spectrometric method. Data presented are the result of the model used.</description>
          <population>Pharmacokinetic (PK) concentration population: all enrolled and treated subjects who had ≥ 1 PK concentration assessed. Active hydroxyacid metabolite p-hydroxyatorvastatin was not included in the model as originally planned as &gt; 80% of samples were below detectable level at the doses used in this trial.</population>
          <units>L/hr</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="553"/>
                    <measurement group_id="O2" value="543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Atorvastatin apparent clearance (CL/F) was described as a function of body weight using an allometric equation. The estimated parameter given is an extrapolation of the model for participants who weigh 70 kg.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Atorvastatin CL/F based on 70 kg BW</param_type>
            <param_value>699</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>570</ci_lower_limit>
            <ci_upper_limit>881</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Pharmacodynamic Responses of Low-density Lipoprotein Cholesterol (LDL-C)</title>
        <description>Low-density lipoprotein cholesterol (LDL-C) measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]). Change from baseline = value at observation minus baseline value.</description>
        <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
        <population>Pharmacodynamic (PD) analysis population: all enrolled subjects who received ≥ 1 dose of study drug and had ≥ 1 PD parameter measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Stayed at 5 mg: Tanner Stage 1</title>
            <description>Atorvastatin 5 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Titrated to 10 mg: Tanner Stage 1</title>
            <description>Atorvastatin: initial dose 5 mg/day through Week 4; after Week 4 dose was doubled to 10 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
          <group group_id="O3">
            <title>Stayed at 10 mg: Tanner Stage 2+</title>
            <description>Atorvastatin 10 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Titrated to 20 mg: Tanner Stage 2+</title>
            <description>Atorvastatin: initial dose 10 mg/day through Week 4; after Week 4 dose was doubled to 20 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Pharmacodynamic Responses of Low-density Lipoprotein Cholesterol (LDL-C)</title>
          <description>Low-density lipoprotein cholesterol (LDL-C) measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]). Change from baseline = value at observation minus baseline value.</description>
          <population>Pharmacodynamic (PD) analysis population: all enrolled subjects who received ≥ 1 dose of study drug and had ≥ 1 PD parameter measurement.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" spread="0.48"/>
                    <measurement group_id="O2" value="6.37" spread="1.10"/>
                    <measurement group_id="O3" value="5.11" spread="0.65"/>
                    <measurement group_id="O4" value="6.23" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.75" spread="0.72"/>
                    <measurement group_id="O2" value="-1.62" spread="0.46"/>
                    <measurement group_id="O3" value="-1.95" spread="0.52"/>
                    <measurement group_id="O4" value="-1.90" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.07" spread="0.50"/>
                    <measurement group_id="O2" value="-1.94" spread="0.56"/>
                    <measurement group_id="O3" value="-2.24" spread="0.57"/>
                    <measurement group_id="O4" value="-2.27" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.89" spread="0.42"/>
                    <measurement group_id="O2" value="-2.57" spread="0.70"/>
                    <measurement group_id="O3" value="-2.12" spread="0.74"/>
                    <measurement group_id="O4" value="-2.55" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.80" spread="0.63"/>
                    <measurement group_id="O2" value="-2.71" spread="0.60"/>
                    <measurement group_id="O3" value="-1.99" spread="0.58"/>
                    <measurement group_id="O4" value="-2.60" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Pharmacodynamic Responses of Low-density Lipoprotein Cholesterol (LDL-C)</title>
        <description>Low-density Lipoprotein Cholesterol (LDL-C): percent (%) change from baseline by treatment over time = [LDL-C at observation minus LDL-C at Week 0] divided by LDL-C at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
        <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
        <population>PD analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Stayed at 5 mg: Tanner Stage 1</title>
            <description>Atorvastatin 5 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Titrated to 10 mg: Tanner Stage 1</title>
            <description>Atorvastatin: initial dose 5 mg/day through Week 4; after Week 4 dose was doubled to 10 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
          <group group_id="O3">
            <title>Stayed at 10 mg: Tanner Stage 2+</title>
            <description>Atorvastatin 10 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Titrated to 20 mg: Tanner Stage 2+</title>
            <description>Atorvastatin: initial dose 10 mg/day through Week 4; after Week 4 dose was doubled to 20 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Pharmacodynamic Responses of Low-density Lipoprotein Cholesterol (LDL-C)</title>
          <description>Low-density Lipoprotein Cholesterol (LDL-C): percent (%) change from baseline by treatment over time = [LDL-C at observation minus LDL-C at Week 0] divided by LDL-C at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
          <population>PD analysis population</population>
          <units>percent change in LDL-C</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.27" spread="14.72"/>
                    <measurement group_id="O2" value="-25.70" spread="7.76"/>
                    <measurement group_id="O3" value="-38.14" spread="9.35"/>
                    <measurement group_id="O4" value="-30.27" spread="9.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.33" spread="8.24"/>
                    <measurement group_id="O2" value="-30.27" spread="5.72"/>
                    <measurement group_id="O3" value="-43.66" spread="7.78"/>
                    <measurement group_id="O4" value="-35.13" spread="12.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.87" spread="7.84"/>
                    <measurement group_id="O2" value="-40.01" spread="6.34"/>
                    <measurement group_id="O3" value="-41.22" spread="11.34"/>
                    <measurement group_id="O4" value="-39.73" spread="10.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.78" spread="11.16"/>
                    <measurement group_id="O2" value="-42.70" spread="6.45"/>
                    <measurement group_id="O3" value="-38.45" spread="7.84"/>
                    <measurement group_id="O4" value="-40.39" spread="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Total Cholesterol (TC)</title>
        <description>Total Cholesterol measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]). Change from baseline = value at observation minus baseline value.</description>
        <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
        <population>PD analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Stayed at 5 mg: Tanner Stage 1</title>
            <description>Atorvastatin 5 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Titrated to 10 mg: Tanner Stage 1</title>
            <description>Atorvastatin: initial dose 5 mg/day through Week 4; after Week 4 dose was doubled to 10 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
          <group group_id="O3">
            <title>Stayed at 10 mg: Tanner Stage 2+</title>
            <description>Atorvastatin 10 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Titrated to 20 mg: Tanner Stage 2+</title>
            <description>Atorvastatin: initial dose 10 mg/day through Week 4; after Week 4 dose was doubled to 20 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Total Cholesterol (TC)</title>
          <description>Total Cholesterol measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]). Change from baseline = value at observation minus baseline value.</description>
          <population>PD analysis population</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.76" spread="0.46"/>
                    <measurement group_id="O2" value="8.58" spread="1.06"/>
                    <measurement group_id="O3" value="6.92" spread="0.71"/>
                    <measurement group_id="O4" value="8.40" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.89" spread="0.79"/>
                    <measurement group_id="O2" value="-2.04" spread="0.69"/>
                    <measurement group_id="O3" value="-2.11" spread="0.53"/>
                    <measurement group_id="O4" value="-2.28" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.27" spread="0.63"/>
                    <measurement group_id="O2" value="-2.24" spread="0.49"/>
                    <measurement group_id="O3" value="-2.37" spread="0.61"/>
                    <measurement group_id="O4" value="-2.66" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.03" spread="0.53"/>
                    <measurement group_id="O2" value="-2.86" spread="0.79"/>
                    <measurement group_id="O3" value="-2.28" spread="0.73"/>
                    <measurement group_id="O4" value="-2.95" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.89" spread="0.44"/>
                    <measurement group_id="O2" value="-3.20" spread="0.65"/>
                    <measurement group_id="O3" value="-2.26" spread="0.69"/>
                    <measurement group_id="O4" value="-3.22" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol (TC)</title>
        <description>Total cholesterol (TC): percent (%) change from baseline by treatment over time = [TC at observation minus TC at Week 0] divided by TC at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
        <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
        <population>PD analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Stayed at 5 mg: Tanner Stage 1</title>
            <description>Atorvastatin 5 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Titrated to 10 mg: Tanner Stage 1</title>
            <description>Atorvastatin: initial dose 5 mg/day through Week 4; after Week 4 dose was doubled to 10 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
          <group group_id="O3">
            <title>Stayed at 10 mg: Tanner Stage 2+</title>
            <description>Atorvastatin 10 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Titrated to 20 mg: Tanner Stage 2+</title>
            <description>Atorvastatin: initial dose 10 mg/day through Week 4; after Week 4 dose was doubled to 20 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol (TC)</title>
          <description>Total cholesterol (TC): percent (%) change from baseline by treatment over time = [TC at observation minus TC at Week 0] divided by TC at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
          <population>PD analysis population</population>
          <units>percent change in TC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.06" spread="11.23"/>
                    <measurement group_id="O2" value="-24.11" spread="8.97"/>
                    <measurement group_id="O3" value="-30.60" spread="7.49"/>
                    <measurement group_id="O4" value="-26.78" spread="7.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.37" spread="7.81"/>
                    <measurement group_id="O2" value="-26.12" spread="4.24"/>
                    <measurement group_id="O3" value="-33.98" spread="7.13"/>
                    <measurement group_id="O4" value="-30.54" spread="11.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.99" spread="8.00"/>
                    <measurement group_id="O2" value="-33.12" spread="6.83"/>
                    <measurement group_id="O3" value="-32.80" spread="8.97"/>
                    <measurement group_id="O4" value="-34.06" spread="9.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.80" spread="5.56"/>
                    <measurement group_id="O2" value="-37.17" spread="5.28"/>
                    <measurement group_id="O3" value="-32.43" spread="8.53"/>
                    <measurement group_id="O4" value="-37.45" spread="9.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Triglycerides (TG)</title>
        <description>Change from baseline in triglycerides measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]). Change from baseline = value at observation minus baseline value.</description>
        <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
        <population>PD analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Stayed at 5 mg: Tanner Stage 1</title>
            <description>Atorvastatin 5 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Titrated to 10 mg: Tanner Stage 1</title>
            <description>Atorvastatin: initial dose 5 mg/day through Week 4; after Week 4 dose was doubled to 10 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
          <group group_id="O3">
            <title>Stayed at 10 mg: Tanner Stage 2+</title>
            <description>Atorvastatin 10 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Titrated to 20 mg: Tanner Stage 2+</title>
            <description>Atorvastatin: initial dose 10 mg/day through Week 4; after Week 4 dose was doubled to 20 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Triglycerides (TG)</title>
          <description>Change from baseline in triglycerides measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]). Change from baseline = value at observation minus baseline value.</description>
          <population>PD analysis population</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.15"/>
                    <measurement group_id="O2" value="0.95" spread="0.27"/>
                    <measurement group_id="O3" value="1.03" spread="0.37"/>
                    <measurement group_id="O4" value="1.20" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.34"/>
                    <measurement group_id="O2" value="-0.08" spread="0.28"/>
                    <measurement group_id="O3" value="0.05" spread="0.68"/>
                    <measurement group_id="O4" value="0.00" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.29"/>
                    <measurement group_id="O2" value="-0.26" spread="0.30"/>
                    <measurement group_id="O3" value="-0.10" spread="0.51"/>
                    <measurement group_id="O4" value="-0.10" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.62"/>
                    <measurement group_id="O2" value="-0.04" spread="0.24"/>
                    <measurement group_id="O3" value="-0.12" spread="0.42"/>
                    <measurement group_id="O4" value="-0.04" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.28"/>
                    <measurement group_id="O2" value="-0.16" spread="0.37"/>
                    <measurement group_id="O3" value="-0.31" spread="0.43"/>
                    <measurement group_id="O4" value="-0.28" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglycerides (TG)</title>
        <description>Triglycerides (TG): percent (%) change from baseline by treatment over time = [TG at observation minus TG at Week 0] divided by TG at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
        <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
        <population>PD analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Stayed at 5 mg: Tanner Stage 1</title>
            <description>Atorvastatin 5 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Titrated to 10 mg: Tanner Stage 1</title>
            <description>Atorvastatin: initial dose 5 mg/day through Week 4; after Week 4 dose was doubled to 10 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
          <group group_id="O3">
            <title>Stayed at 10 mg: Tanner Stage 2+</title>
            <description>Atorvastatin 10 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Titrated to 20 mg: Tanner Stage 2+</title>
            <description>Atorvastatin: initial dose 10 mg/day through Week 4; after Week 4 dose was doubled to 20 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides (TG)</title>
          <description>Triglycerides (TG): percent (%) change from baseline by treatment over time = [TG at observation minus TG at Week 0] divided by TG at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
          <population>PD analysis population</population>
          <units>percent change in TG</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.66" spread="38.26"/>
                    <measurement group_id="O2" value="-6.87" spread="29.08"/>
                    <measurement group_id="O3" value="28.37" spread="85.32"/>
                    <measurement group_id="O4" value="-0.56" spread="32.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.20" spread="32.55"/>
                    <measurement group_id="O2" value="-21.43" spread="30.42"/>
                    <measurement group_id="O3" value="1.27" spread="50.81"/>
                    <measurement group_id="O4" value="-7.60" spread="25.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.06" spread="78.73"/>
                    <measurement group_id="O2" value="-1.27" spread="23.91"/>
                    <measurement group_id="O3" value="-4.43" spread="32.52"/>
                    <measurement group_id="O4" value="-2.72" spread="24.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="31.48"/>
                    <measurement group_id="O2" value="-9.88" spread="33.31"/>
                    <measurement group_id="O3" value="-20.94" spread="39.24"/>
                    <measurement group_id="O4" value="-21.11" spread="23.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C)</title>
        <description>Change from baseline in high-density lipoprotein cholesterol measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]). Change from baseline = value at observation minus baseline value.</description>
        <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
        <population>PD analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Stayed at 5 mg: Tanner Stage 1</title>
            <description>Atorvastatin 5 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Titrated to 10 mg: Tanner Stage 1</title>
            <description>Atorvastatin: initial dose 5 mg/day through Week 4; after Week 4 dose was doubled to 10 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
          <group group_id="O3">
            <title>Stayed at 10 mg: Tanner Stage 2+</title>
            <description>Atorvastatin 10 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Titrated to 20 mg: Tanner Stage 2+</title>
            <description>Atorvastatin: initial dose 10 mg/day through Week 4; after Week 4 dose was doubled to 20 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C)</title>
          <description>Change from baseline in high-density lipoprotein cholesterol measured in millimoles per liter (mmol/L); assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]). Change from baseline = value at observation minus baseline value.</description>
          <population>PD analysis population</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="0.12"/>
                    <measurement group_id="O2" value="1.45" spread="0.29"/>
                    <measurement group_id="O3" value="1.17" spread="0.18"/>
                    <measurement group_id="O4" value="1.18" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.24"/>
                    <measurement group_id="O2" value="-0.10" spread="0.29"/>
                    <measurement group_id="O3" value="-0.05" spread="0.26"/>
                    <measurement group_id="O4" value="-0.01" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.05"/>
                    <measurement group_id="O2" value="0.00" spread="0.19"/>
                    <measurement group_id="O3" value="0.02" spread="0.21"/>
                    <measurement group_id="O4" value="-0.01" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.29"/>
                    <measurement group_id="O2" value="-0.01" spread="0.18"/>
                    <measurement group_id="O3" value="0.04" spread="0.14"/>
                    <measurement group_id="O4" value="-0.03" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.22"/>
                    <measurement group_id="O2" value="-0.07" spread="0.21"/>
                    <measurement group_id="O3" value="0.08" spread="0.25"/>
                    <measurement group_id="O4" value="-0.08" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C)</title>
        <description>High-density lipoprotein cholesterol (HDL-C): percent (%) change by treatment over time = [HDL-C at observation minus HDL-C at Week 0] divided by HDL-C at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
        <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
        <population>PD analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Stayed at 5 mg: Tanner Stage 1</title>
            <description>Atorvastatin 5 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Titrated to 10 mg: Tanner Stage 1</title>
            <description>Atorvastatin: initial dose 5 mg/day through Week 4; after Week 4 dose was doubled to 10 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
          <group group_id="O3">
            <title>Stayed at 10 mg: Tanner Stage 2+</title>
            <description>Atorvastatin 10 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Titrated to 20 mg: Tanner Stage 2+</title>
            <description>Atorvastatin: initial dose 10 mg/day through Week 4; after Week 4 dose was doubled to 20 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C)</title>
          <description>High-density lipoprotein cholesterol (HDL-C): percent (%) change by treatment over time = [HDL-C at observation minus HDL-C at Week 0] divided by HDL-C at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
          <population>PD analysis population</population>
          <units>percent change in HDL-C</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.38" spread="17.32"/>
                    <measurement group_id="O2" value="-6.45" spread="21.01"/>
                    <measurement group_id="O3" value="-4.11" spread="19.96"/>
                    <measurement group_id="O4" value="-0.77" spread="17.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.99" spread="3.90"/>
                    <measurement group_id="O2" value="1.59" spread="13.18"/>
                    <measurement group_id="O3" value="1.04" spread="17.38"/>
                    <measurement group_id="O4" value="1.77" spread="23.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.18" spread="22.70"/>
                    <measurement group_id="O2" value="-0.64" spread="10.35"/>
                    <measurement group_id="O3" value="3.28" spread="11.63"/>
                    <measurement group_id="O4" value="-2.78" spread="21.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="15.02"/>
                    <measurement group_id="O2" value="-2.84" spread="14.49"/>
                    <measurement group_id="O3" value="5.99" spread="21.02"/>
                    <measurement group_id="O4" value="-5.19" spread="17.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Apolipoprotein A-1 (Apo A-1)</title>
        <description>Change from baseline in Apolipoprotein A-1 measured in grams per liter (g/L); assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]). Change from baseline = value at observation minus baseline value.</description>
        <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
        <population>PD analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Stayed at 5 mg: Tanner Stage 1</title>
            <description>Atorvastatin 5 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Titrated to 10 mg: Tanner Stage 1</title>
            <description>Atorvastatin: initial dose 5 mg/day through Week 4; after Week 4 dose was doubled to 10 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
          <group group_id="O3">
            <title>Stayed at 10 mg: Tanner Stage 2+</title>
            <description>Atorvastatin 10 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Titrated to 20 mg: Tanner Stage 2+</title>
            <description>Atorvastatin: initial dose 10 mg/day through Week 4; after Week 4 dose was doubled to 20 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Apolipoprotein A-1 (Apo A-1)</title>
          <description>Change from baseline in Apolipoprotein A-1 measured in grams per liter (g/L); assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]). Change from baseline = value at observation minus baseline value.</description>
          <population>PD analysis population</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.20"/>
                    <measurement group_id="O2" value="1.45" spread="0.20"/>
                    <measurement group_id="O3" value="1.29" spread="0.20"/>
                    <measurement group_id="O4" value="1.24" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.17"/>
                    <measurement group_id="O2" value="-0.08" spread="0.23"/>
                    <measurement group_id="O3" value="-0.09" spread="0.22"/>
                    <measurement group_id="O4" value="-0.01" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.14"/>
                    <measurement group_id="O2" value="-0.06" spread="0.13"/>
                    <measurement group_id="O3" value="-0.06" spread="0.21"/>
                    <measurement group_id="O4" value="0.07" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.18"/>
                    <measurement group_id="O2" value="-0.02" spread="0.11"/>
                    <measurement group_id="O3" value="-0.07" spread="0.19"/>
                    <measurement group_id="O4" value="-0.04" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.12"/>
                    <measurement group_id="O2" value="-0.05" spread="0.13"/>
                    <measurement group_id="O3" value="-0.04" spread="0.24"/>
                    <measurement group_id="O4" value="-0.07" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1)</title>
        <description>Apolipoprotein A-1 (Apo A-1): percent (%) change from baseline by treatment over time = [Apo A-1 at observation minus Apo A-1 at Week 0] divided by Apo A-1 at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
        <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
        <population>PD analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Stayed at 5 mg: Tanner Stage 1</title>
            <description>Atorvastatin 5 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Titrated to 10 mg: Tanner Stage 1</title>
            <description>Atorvastatin: initial dose 5 mg/day through Week 4; after Week 4 dose was doubled to 10 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
          <group group_id="O3">
            <title>Stayed at 10 mg: Tanner Stage 2+</title>
            <description>Atorvastatin 10 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Titrated to 20 mg: Tanner Stage 2+</title>
            <description>Atorvastatin: initial dose 10 mg/day through Week 4; after Week 4 dose was doubled to 20 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1)</title>
          <description>Apolipoprotein A-1 (Apo A-1): percent (%) change from baseline by treatment over time = [Apo A-1 at observation minus Apo A-1 at Week 0] divided by Apo A-1 at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
          <population>PD analysis population</population>
          <units>percent change in Apo A-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="11.21"/>
                    <measurement group_id="O2" value="-5.24" spread="15.86"/>
                    <measurement group_id="O3" value="-5.96" spread="16.76"/>
                    <measurement group_id="O4" value="-0.53" spread="11.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.15" spread="8.20"/>
                    <measurement group_id="O2" value="-3.30" spread="8.11"/>
                    <measurement group_id="O3" value="-3.73" spread="16.43"/>
                    <measurement group_id="O4" value="7.54" spread="25.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.90" spread="14.01"/>
                    <measurement group_id="O2" value="-0.97" spread="7.04"/>
                    <measurement group_id="O3" value="-4.21" spread="14.81"/>
                    <measurement group_id="O4" value="-2.82" spread="18.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="8.49"/>
                    <measurement group_id="O2" value="-3.37" spread="9.35"/>
                    <measurement group_id="O3" value="-2.60" spread="20.22"/>
                    <measurement group_id="O4" value="-4.82" spread="16.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Apolipoprotein B (Apo B)</title>
        <description>Change from baseline in Apolipoprotein B measured in grams per liter (g/L); assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]). Change from baseline = value at observation minus baseline value.</description>
        <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
        <population>PD analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Stayed at 5 mg: Tanner Stage 1</title>
            <description>Atorvastatin 5 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Titrated to 10 mg: Tanner Stage 1</title>
            <description>Atorvastatin: initial dose 5 mg/day through Week 4; after Week 4 dose was doubled to 10 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
          <group group_id="O3">
            <title>Stayed at 10 mg: Tanner Stage 2+</title>
            <description>Atorvastatin 10 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Titrated to 20 mg: Tanner Stage 2+</title>
            <description>Atorvastatin: initial dose 10 mg/day through Week 4; after Week 4 dose was doubled to 20 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Apolipoprotein B (Apo B)</title>
          <description>Change from baseline in Apolipoprotein B measured in grams per liter (g/L); assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]). Change from baseline = value at observation minus baseline value.</description>
          <population>PD analysis population</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="0.13"/>
                    <measurement group_id="O2" value="1.49" spread="0.24"/>
                    <measurement group_id="O3" value="1.26" spread="0.14"/>
                    <measurement group_id="O4" value="1.52" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.13"/>
                    <measurement group_id="O2" value="-0.31" spread="0.19"/>
                    <measurement group_id="O3" value="-0.39" spread="0.14"/>
                    <measurement group_id="O4" value="-0.42" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.11"/>
                    <measurement group_id="O2" value="-0.40" spread="0.13"/>
                    <measurement group_id="O3" value="-0.44" spread="0.10"/>
                    <measurement group_id="O4" value="-0.47" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.15"/>
                    <measurement group_id="O2" value="-0.53" spread="0.17"/>
                    <measurement group_id="O3" value="-0.42" spread="0.15"/>
                    <measurement group_id="O4" value="-0.52" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.08"/>
                    <measurement group_id="O2" value="-0.59" spread="0.15"/>
                    <measurement group_id="O3" value="-0.41" spread="0.17"/>
                    <measurement group_id="O4" value="-0.49" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B (Apo B)</title>
        <description>Apolipoprotein B (Apo B): percent (%) change from baseline by treatment over time = [Apo B at observation minus Apo B at Week 0] divided by Apo B at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
        <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
        <population>PD analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Stayed at 5 mg: Tanner Stage 1</title>
            <description>Atorvastatin 5 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Titrated to 10 mg: Tanner Stage 1</title>
            <description>Atorvastatin: initial dose 5 mg/day through Week 4; after Week 4 dose was doubled to 10 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
          <group group_id="O3">
            <title>Stayed at 10 mg: Tanner Stage 2+</title>
            <description>Atorvastatin 10 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Titrated to 20 mg: Tanner Stage 2+</title>
            <description>Atorvastatin: initial dose 10 mg/day through Week 4; after Week 4 dose was doubled to 20 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B (Apo B)</title>
          <description>Apolipoprotein B (Apo B): percent (%) change from baseline by treatment over time = [Apo B at observation minus Apo B at Week 0] divided by Apo B at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
          <population>PD analysis population</population>
          <units>percent change in Apo B</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.92" spread="13.97"/>
                    <measurement group_id="O2" value="-19.88" spread="10.96"/>
                    <measurement group_id="O3" value="-30.81" spread="10.27"/>
                    <measurement group_id="O4" value="-27.46" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.89" spread="8.94"/>
                    <measurement group_id="O2" value="-26.56" spread="5.33"/>
                    <measurement group_id="O3" value="-34.69" spread="6.10"/>
                    <measurement group_id="O4" value="-30.42" spread="11.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.58" spread="12.96"/>
                    <measurement group_id="O2" value="-35.26" spread="6.85"/>
                    <measurement group_id="O3" value="-33.26" spread="10.38"/>
                    <measurement group_id="O4" value="-33.61" spread="9.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.39" spread="5.97"/>
                    <measurement group_id="O2" value="-39.59" spread="5.83"/>
                    <measurement group_id="O3" value="-31.94" spread="11.64"/>
                    <measurement group_id="O4" value="-31.26" spread="18.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C)</title>
        <description>Change from baseline in very low-density lipoprotein-cholesterol (VLDL-C) measured in millimoles per liter (mmol/L). Change from baseline = value at observation minus baseline value. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
        <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
        <population>PD analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Stayed at 5 mg: Tanner Stage 1</title>
            <description>Atorvastatin 5 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Titrated to 10 mg: Tanner Stage 1</title>
            <description>Atorvastatin: initial dose 5 mg/day through Week 4; after Week 4 dose was doubled to 10 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
          <group group_id="O3">
            <title>Stayed at 10 mg: Tanner Stage 2+</title>
            <description>Atorvastatin 10 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Titrated to 20 mg: Tanner Stage 2+</title>
            <description>Atorvastatin: initial dose 10 mg/day through Week 4; after Week 4 dose was doubled to 20 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C)</title>
          <description>Change from baseline in very low-density lipoprotein-cholesterol (VLDL-C) measured in millimoles per liter (mmol/L). Change from baseline = value at observation minus baseline value. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
          <population>PD analysis population</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.15"/>
                    <measurement group_id="O2" value="0.76" spread="0.30"/>
                    <measurement group_id="O3" value="0.65" spread="0.11"/>
                    <measurement group_id="O4" value="0.99" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.12"/>
                    <measurement group_id="O2" value="-0.31" spread="0.38"/>
                    <measurement group_id="O3" value="-0.12" spread="0.29"/>
                    <measurement group_id="O4" value="-0.38" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.24"/>
                    <measurement group_id="O2" value="-0.30" spread="0.27"/>
                    <measurement group_id="O3" value="-0.14" spread="0.24"/>
                    <measurement group_id="O4" value="-0.39" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.17"/>
                    <measurement group_id="O2" value="-0.28" spread="0.32"/>
                    <measurement group_id="O3" value="-0.20" spread="0.17"/>
                    <measurement group_id="O4" value="-0.36" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.32"/>
                    <measurement group_id="O2" value="-0.42" spread="0.28"/>
                    <measurement group_id="O3" value="-0.35" spread="0.14"/>
                    <measurement group_id="O4" value="-0.55" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C)</title>
        <description>Very low-density lipoprotein-cholesterol (VLDL-C): percent (%) change from baseline by treatment over time = [VLDL-C at observation minus VLDL-C at Week 0] divided by VLDL-C at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
        <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8</time_frame>
        <population>PD analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Stayed at 5 mg: Tanner Stage 1</title>
            <description>Atorvastatin 5 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Titrated to 10 mg: Tanner Stage 1</title>
            <description>Atorvastatin: initial dose 5 mg/day through Week 4; after Week 4 dose was doubled to 10 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
          <group group_id="O3">
            <title>Stayed at 10 mg: Tanner Stage 2+</title>
            <description>Atorvastatin 10 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Titrated to 20 mg: Tanner Stage 2+</title>
            <description>Atorvastatin: initial dose 10 mg/day through Week 4; after Week 4 dose was doubled to 20 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C)</title>
          <description>Very low-density lipoprotein-cholesterol (VLDL-C): percent (%) change from baseline by treatment over time = [VLDL-C at observation minus VLDL-C at Week 0] divided by VLDL-C at Week 0 * 100. Assessments were performed in the fasting state (minimum 10-hour fast [optional at Weeks 2 and 6]).</description>
          <population>PD analysis population</population>
          <units>percent change in VLDL-C</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.20" spread="25.17"/>
                    <measurement group_id="O2" value="-28.49" spread="43.50"/>
                    <measurement group_id="O3" value="-14.50" spread="41.19"/>
                    <measurement group_id="O4" value="-39.95" spread="37.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.66" spread="48.66"/>
                    <measurement group_id="O2" value="-31.86" spread="37.62"/>
                    <measurement group_id="O3" value="-21.10" spread="37.56"/>
                    <measurement group_id="O4" value="-36.35" spread="28.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.10" spread="36.46"/>
                    <measurement group_id="O2" value="-25.59" spread="44.90"/>
                    <measurement group_id="O3" value="-29.20" spread="25.11"/>
                    <measurement group_id="O4" value="-35.08" spread="25.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.31" spread="57.38"/>
                    <measurement group_id="O2" value="-50.29" spread="21.44"/>
                    <measurement group_id="O3" value="-53.61" spread="19.21"/>
                    <measurement group_id="O4" value="-52.38" spread="29.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Flow-Mediated Dilatation at Week 8</title>
        <description>Brachial artery flow-mediated dilatation (FMD) = (max minus baseline diameter divided by baseline diameter) x 100%. Standardized image acquisition: brachial artery images recorded for one minute at rest, blood pressure cuff inflated to 250 mm Hg for 5 minutes with brachial artery imaged continuously throughout cuff inflation, cuff released to produce reactive hyperaemia and the brachial artery imaged continuously for 3 minutes after release. Total duration of measurement approximately 25 minutes. Change from baseline = value at observation minus baseline value.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>PD analysis population. Flow-mediated dilation (FMD) was measured at centers with established FMD facilities.</population>
        <group_list>
          <group group_id="O1">
            <title>Stayed at 5 mg: Tanner Stage 1</title>
            <description>Atorvastatin 5 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Titrated to 10 mg: Tanner Stage 1</title>
            <description>Atorvastatin: initial dose 5 mg/day through Week 4; after Week 4 dose was doubled to 10 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
          <group group_id="O3">
            <title>Stayed at 10 mg: Tanner Stage 2+</title>
            <description>Atorvastatin 10 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Titrated to 20 mg: Tanner Stage 2+</title>
            <description>Atorvastatin: initial dose 10 mg/day through Week 4; after Week 4 dose was doubled to 20 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Flow-Mediated Dilatation at Week 8</title>
          <description>Brachial artery flow-mediated dilatation (FMD) = (max minus baseline diameter divided by baseline diameter) x 100%. Standardized image acquisition: brachial artery images recorded for one minute at rest, blood pressure cuff inflated to 250 mm Hg for 5 minutes with brachial artery imaged continuously throughout cuff inflation, cuff released to produce reactive hyperaemia and the brachial artery imaged continuously for 3 minutes after release. Total duration of measurement approximately 25 minutes. Change from baseline = value at observation minus baseline value.</description>
          <population>PD analysis population. Flow-mediated dilation (FMD) was measured at centers with established FMD facilities.</population>
          <units>FMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.34" spread="3.15"/>
                    <measurement group_id="O2" value="7.41" spread="3.30"/>
                    <measurement group_id="O3" value="5.05" spread="3.86"/>
                    <measurement group_id="O4" value="3.67" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="2.32"/>
                    <measurement group_id="O2" value="-1.14" spread="1.47"/>
                    <measurement group_id="O3" value="-0.32" spread="4.83"/>
                    <measurement group_id="O4" value="1.35" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Flow-Mediated Dilatation at Week 8</title>
        <description>Brachial Flow-Mediated Dilatation (FMD) = (max minus baseline diameter divided by baseline diameter) x 100%.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>PD analysis population. Flow-mediated dilation (FMD) was measured at centers with established FMD facilities.</population>
        <group_list>
          <group group_id="O1">
            <title>Stayed at 5 mg: Tanner Stage 1</title>
            <description>Atorvastatin 5 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Titrated to 10 mg: Tanner Stage 1</title>
            <description>Atorvastatin: initial dose 5 mg/day through Week 4; after Week 4 dose was doubled to 10 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
          <group group_id="O3">
            <title>Stayed at 10 mg: Tanner Stage 2+</title>
            <description>Atorvastatin 10 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Titrated to 20 mg: Tanner Stage 2+</title>
            <description>Atorvastatin: initial dose 10 mg/day through Week 4; after Week 4 dose was doubled to 20 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Flow-Mediated Dilatation at Week 8</title>
          <description>Brachial Flow-Mediated Dilatation (FMD) = (max minus baseline diameter divided by baseline diameter) x 100%.</description>
          <population>PD analysis population. Flow-mediated dilation (FMD) was measured at centers with established FMD facilities.</population>
          <units>percent change in FMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.19" spread="23.67"/>
                    <measurement group_id="O2" value="-20.77" spread="37.03"/>
                    <measurement group_id="O3" value="-9.77" spread="63.20"/>
                    <measurement group_id="O4" value="1.49" spread="28.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Apparent Volume of Distribution of the Central Compartment (Vc/F)</title>
        <description>Parent-metabolite population PK model built using sparse blood samples from Tanner Stages 1 and 2+. Sampling times: Weeks 2 + 6: single sample between 4 -12 hours postdose; Weeks 4 + 8: predose, 1 + 2 hours postdose. Plasma samples analyzed for atorvastatin and active hydroxyacid metabolite (o-hydroxyatorvastatin) concentrations using validated, sensitive, specific high-performance liquid chromatography tandem mass spectrometric method. Vc/F value based on 70 kg body weight. Parameter estimation uncertainty (95% CI) by non-parametric bootstrap analysis. Data presented are result of model used.</description>
        <time_frame>Week 2, Week 4, Week 6, Week 8</time_frame>
        <population>Pharmacokinetic (PK) concentration population: all enrolled and treated subjects who had ≥ 1 PK concentration assessed. Active hydroxyacid metabolite p-hydroxyatorvastatin was not included in the model as originally planned as &gt; 80% of samples were below detectable level at the doses used in this trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin (5 mg, 10 mg, 20 mg): Tanner Stages 1 and 2+</title>
            <description>Tanner Stage 1: Initial dose 5 mg/day through Week 4; after Week 4 dose may have been doubled to 10 mg/day if target LDL-C was not attained and study drug was well tolerated; Tanner Stage 2+: Initial dose 10 mg/day through Week 4; after Week 4 dose may have been doubled to 20 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Apparent Volume of Distribution of the Central Compartment (Vc/F)</title>
          <description>Parent-metabolite population PK model built using sparse blood samples from Tanner Stages 1 and 2+. Sampling times: Weeks 2 + 6: single sample between 4 -12 hours postdose; Weeks 4 + 8: predose, 1 + 2 hours postdose. Plasma samples analyzed for atorvastatin and active hydroxyacid metabolite (o-hydroxyatorvastatin) concentrations using validated, sensitive, specific high-performance liquid chromatography tandem mass spectrometric method. Vc/F value based on 70 kg body weight. Parameter estimation uncertainty (95% CI) by non-parametric bootstrap analysis. Data presented are result of model used.</description>
          <population>Pharmacokinetic (PK) concentration population: all enrolled and treated subjects who had ≥ 1 PK concentration assessed. Active hydroxyacid metabolite p-hydroxyatorvastatin was not included in the model as originally planned as &gt; 80% of samples were below detectable level at the doses used in this trial.</population>
          <units>liters</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1020" lower_limit="209" upper_limit="2210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Subjects (5 mg, 10 mg): Tanner Stage 1</title>
          <description>Atorvastatin: subjects who stayed at initial dose of 5 mg/day for duration of study and subjects who titrated after Week 4 to 10 mg/day if target LDL-C was not attained and study drug was well tolerated.</description>
        </group>
        <group group_id="E2">
          <title>All Subjects (10 mg, 20 mg): Tanner Stage 2+</title>
          <description>Atorvastatin: subjects who stayed at initial dose of 10 mg/day for duration of study and subjects who titrated to 20 mg/day after Week 4 if target LDL-C was not attained and study drug was well tolerated.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Viral rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt; 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt; 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

